Alan Luk

Alan Luk is Vice President, CMC for Trishula Therapeutics and is responsible for leading the planning and execution of the TTX-030 program CMC strategy. He brings with him over 20 years of biotech experience working on research programs from early stage to commercial.

Prior to joining Trishula, Alan served as the Director of CMC at Tizona Therapeutics overseeing the TTX-030 program. In this role, he assisted in establishing the overall strategy for process development and manufacturing to support Tizona’s preclinical and clinical programs. Previously, Alan held various positions of increasing responsibility in process development, clinical manufacturing, technology transfer, and external manufacturing at companies including FibroGen and BioMarin Pharmaceuticals.

Alan holds a Bachelor of Science in Biochemistry from the University of California, Davis and a MBA from San Francisco State University.